View Future GrowthAlgorae Pharmaceuticals 過去の業績過去 基準チェック /06Algorae Pharmaceuticalsは5.8%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで36.2%毎年増加している。売上は減少しており、年平均90.1%の割合である。主要情報5.80%収益成長率28.76%EPS成長率Biotechs 業界の成長17.04%収益成長率-90.07%株主資本利益率-53.66%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million.Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,350,001 Price\Range: AUD 0.012 Transaction Features: Subsequent Direct Listingお知らせ • Aug 14Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025.お知らせ • Apr 03Algorae Pharmaceuticals Limited Announces the Appointment of Vishal Shah as Chief Commercial OfficerAlgorae Pharmaceuticals Limited announced the appointment of seasoned pharmaceutical executive Vishal Shah as Chief Commercial Officer (`CCO'). With a distinguished career spanning over 20 years in pharmaceuticals, biotechnology, and healthcare, Mr. Shah will spearhead Algorae's commercial strategy to accelerate growth and expansion into complimentary pharmaceutical market segments. Mr. Shah joins Algorae from HPS Pharmacies, where he was responsible for shaping procurement strategy, driving revenue growth, and expanding market reach. At HPS Pharmacies, he was instrumental in accelerating business expansion, strengthening the Company's market position, and forging high-value partnerships. Prior to EBOS, Mr. Shah held senior leadership roles at Baxter Healthcare, including Associate Director of Pharmaceuticals for Asia-Pacific (`APAC') and Head of Pharmaceuticals Australia/New Zealand (`ANZ'). At Baxter, a global leader in medical technology and pharmaceuticals with a market capitalisation exceeding AUD 27 billion, he successfully led commercial strategy, executed major product launches, and oversaw growth initiatives that enhanced both revenue and earnings. His expertise spans navigating regulatory landscapes, establishing strategic alliances, and optimising commercial operations across international markets. Mr. Shah has a Pharmacy Degree, a Master's in Applied Science (Biotechnology), and an MBA from Western Sydney University, providing him with of the necessary scientific expertise and commercial acumen for his new role with Algorae.お知らせ • Sep 06Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024.お知らせ • Jul 01Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited announced the appointment of Ms Jennifer Voon as Company Secretary, effective 1 July 2024. Ms Voon is a Chartered Accountant with over a decade's experience in financial services, with a focus on capital markets and compliance. Ms Maria Clemente of Automic Group will step down as Company Secretary effectively immediately.お知らせ • Jan 17Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited advised that Mr. Madhukar Bhalla has resigned as Company Secretary of the Company, effective 17 January 2024. Mr. Bhalla has tendered his resignation from the Company and will be replaced by Ms Leah Pieris of Automic Group as Company Secretary, with effect from 17 January 2024. Ms Pieris is a Chartered Company Secretary and a Fellow of the Governance Institute of Australia. Ms Pieris is a member of Automic Group, which provides market leading, cloud based share registry technology, compliance and governance solutions, supported by a tailored range of professional services. As a member of Automic Group’s Company Secretary team, Ms Pieris assists ASX listed companies across a range of industries.お知らせ • Sep 12Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023, at 12:00 E. Australia Standard Time.お知らせ • Jul 29Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023, at 12:00 E. Australia Standard Time. Location: Thomson Geer Level 23, Rialto South Tower, 525 Collins Street, Melbourne Australia Agenda: To consider change of company name; to ratification of the issue of shares and options under the pre-Entitlement offer placement; to consider Ratification of the issue of Shares and Options under the Greenshoe Placement; to consider Ratification of the issue of Lead Manager Options; to consider and Approve of the issue of Lead Manager Options; to consider and Approve of the issue of Performance Shares to David Hainsworth; and to consider and Approve of the issue of Performance Shares to Brad Dilkes.お知らせ • Jul 04Living Cell Technologies Limited Announces Management ChangesLiving Cell Technologies Limited (LCT) announced that it has made the following changes to its board of directors: the appointment of Mr. Bradley Latham as a non-executive director of LCT, effective immediately, the appointment of Professor Carolyn Sue to the position of Chief Medical Officer (CMO) of NTCELL and simultaneous resignation from her non-executive director position, effective 1 July 2023. Mr. Latham is an accomplished and energetic businessperson with strong commercial acumen and extensive business experience. The majority of Mr. Latham's working career has been with Sydney Markets where he has worked his way through the ranks until appointed CEO of the group in 2006. Mr. Latham is experienced in all matters of business, including strategic planning, financial management, business development, operational management, and marketing of various successful brands, which has been instrumental in maintaining Sydney Markets' position as one of the premier privately owned markets in the world. Mr. Latham has a proven track record of business leadership and has a strong understanding of good corporate governance and risk management. He possesses an ability to identify and assess strategic growth opportunities, which is advantageous for LCT as it assesses various potential opportunities to expand and diversify its drug candidate profile. Mr. Latham holds a Master of Management from the University of New South Wales. Professor Carolyn Sue, MBBS, PhD, FRACP, is an internationally recognised clinician-scientist, a leader in Parkinson's disease and a medicine alum of UNSW who trained at Westmead Hospital and at Columbia University in the United States. Carolyn's experience, expertise and contributions to Parkinson's disease research have been widely recognised. She holds leadership roles in the Movement Disorder Society of Australia and New Zealand, and International Parkinson's disease and Movement Disorder Society, and is a Fellow of the Australian Academy of Medical Sciences. In 2019, Carolyn was awarded a member of the Order of Australia (AM) in recognition of her significant services to medicine. Professor Sue is leading a scientific review of the NTCELL clinical trial protocol and development plan in conjunction with a multi-disciplinary panel of scientific experts advising on various aspects of the NTCELL project. Professor Sue has resigned from her non-executive director position to focus all necessary attention on the role of CMO of NTCELL.お知らせ • Jun 09Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific OfficerLiving Cell Technologies Limited announced the appointment of Dr. James A Mckenna as Chief Scientific Officer (`CSO') of the Company. Dr. Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne. Dr. Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration. Dr. Mckenna's appointment coincides with LCT's corporate strategy to expand and diversify the Company's development pipeline. The role of CSO will include: research pertaining to drug candidate development, arrangement of pre-clinical and clinical studies, and liaison with intellectual property attorneys and pharmaceutical regulators. Dr. Mckenna commences the role of CSO on 19 June 2023.収支内訳Algorae Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:LVCL.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 250-10130 Sep 250-10130 Jun 250-10131 Mar 250-10131 Dec 240-10130 Sep 240-21130 Jun 240-21131 Mar 240-21131 Dec 230-21130 Sep 230-21130 Jun 230-20131 Mar 230-20231 Dec 220-30230 Sep 220-20230 Jun 220-20131 Mar 220-20231 Dec 210-20230 Sep 210-20230 Jun 210-10231 Mar 210-10231 Dec 200-10230 Sep 200-10230 Jun 201-10231 Mar 201-10231 Dec 191-20230 Sep 191-30330 Jun 191-30331 Mar 191-20331 Dec 18100330 Sep 18100330 Jun 18100331 Mar 181-20431 Dec 171-40430 Sep 171-40430 Jun 171-40431 Mar 171-40431 Dec 161-40430 Sep 161-30430 Jun 161-30331 Mar 161-51331 Dec 150-62230 Sep 151-72230 Jun 151-722質の高い収益: LVCL.Fは現在利益が出ていません。利益率の向上: LVCL.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: LVCL.Fは利益を出していないが、過去 5 年間で年間5.8%の割合で損失を削減してきた。成長の加速: LVCL.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: LVCL.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: LVCL.Fは現在利益が出ていないため、自己資本利益率 ( -53.66% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 15:49終値2026/05/28 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Algorae Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million.Algorae Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 1.0722 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 89,350,001 Price\Range: AUD 0.012 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 14Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 02, 2025.
お知らせ • Apr 03Algorae Pharmaceuticals Limited Announces the Appointment of Vishal Shah as Chief Commercial OfficerAlgorae Pharmaceuticals Limited announced the appointment of seasoned pharmaceutical executive Vishal Shah as Chief Commercial Officer (`CCO'). With a distinguished career spanning over 20 years in pharmaceuticals, biotechnology, and healthcare, Mr. Shah will spearhead Algorae's commercial strategy to accelerate growth and expansion into complimentary pharmaceutical market segments. Mr. Shah joins Algorae from HPS Pharmacies, where he was responsible for shaping procurement strategy, driving revenue growth, and expanding market reach. At HPS Pharmacies, he was instrumental in accelerating business expansion, strengthening the Company's market position, and forging high-value partnerships. Prior to EBOS, Mr. Shah held senior leadership roles at Baxter Healthcare, including Associate Director of Pharmaceuticals for Asia-Pacific (`APAC') and Head of Pharmaceuticals Australia/New Zealand (`ANZ'). At Baxter, a global leader in medical technology and pharmaceuticals with a market capitalisation exceeding AUD 27 billion, he successfully led commercial strategy, executed major product launches, and oversaw growth initiatives that enhanced both revenue and earnings. His expertise spans navigating regulatory landscapes, establishing strategic alliances, and optimising commercial operations across international markets. Mr. Shah has a Pharmacy Degree, a Master's in Applied Science (Biotechnology), and an MBA from Western Sydney University, providing him with of the necessary scientific expertise and commercial acumen for his new role with Algorae.
お知らせ • Sep 06Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024Algorae Pharmaceuticals Limited, Annual General Meeting, Oct 25, 2024.
お知らせ • Jul 01Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited announced the appointment of Ms Jennifer Voon as Company Secretary, effective 1 July 2024. Ms Voon is a Chartered Accountant with over a decade's experience in financial services, with a focus on capital markets and compliance. Ms Maria Clemente of Automic Group will step down as Company Secretary effectively immediately.
お知らせ • Jan 17Algorae Pharmaceuticals Limited Announces Change of Company SecretaryAlgorae Pharmaceuticals Limited advised that Mr. Madhukar Bhalla has resigned as Company Secretary of the Company, effective 17 January 2024. Mr. Bhalla has tendered his resignation from the Company and will be replaced by Ms Leah Pieris of Automic Group as Company Secretary, with effect from 17 January 2024. Ms Pieris is a Chartered Company Secretary and a Fellow of the Governance Institute of Australia. Ms Pieris is a member of Automic Group, which provides market leading, cloud based share registry technology, compliance and governance solutions, supported by a tailored range of professional services. As a member of Automic Group’s Company Secretary team, Ms Pieris assists ASX listed companies across a range of industries.
お知らせ • Sep 12Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023Algorae Pharmaceuticals Limited, Annual General Meeting, Nov 02, 2023, at 12:00 E. Australia Standard Time.
お知らせ • Jul 29Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023Living Cell Technologies Limited, Annual General Meeting, Sep 01, 2023, at 12:00 E. Australia Standard Time. Location: Thomson Geer Level 23, Rialto South Tower, 525 Collins Street, Melbourne Australia Agenda: To consider change of company name; to ratification of the issue of shares and options under the pre-Entitlement offer placement; to consider Ratification of the issue of Shares and Options under the Greenshoe Placement; to consider Ratification of the issue of Lead Manager Options; to consider and Approve of the issue of Lead Manager Options; to consider and Approve of the issue of Performance Shares to David Hainsworth; and to consider and Approve of the issue of Performance Shares to Brad Dilkes.
お知らせ • Jul 04Living Cell Technologies Limited Announces Management ChangesLiving Cell Technologies Limited (LCT) announced that it has made the following changes to its board of directors: the appointment of Mr. Bradley Latham as a non-executive director of LCT, effective immediately, the appointment of Professor Carolyn Sue to the position of Chief Medical Officer (CMO) of NTCELL and simultaneous resignation from her non-executive director position, effective 1 July 2023. Mr. Latham is an accomplished and energetic businessperson with strong commercial acumen and extensive business experience. The majority of Mr. Latham's working career has been with Sydney Markets where he has worked his way through the ranks until appointed CEO of the group in 2006. Mr. Latham is experienced in all matters of business, including strategic planning, financial management, business development, operational management, and marketing of various successful brands, which has been instrumental in maintaining Sydney Markets' position as one of the premier privately owned markets in the world. Mr. Latham has a proven track record of business leadership and has a strong understanding of good corporate governance and risk management. He possesses an ability to identify and assess strategic growth opportunities, which is advantageous for LCT as it assesses various potential opportunities to expand and diversify its drug candidate profile. Mr. Latham holds a Master of Management from the University of New South Wales. Professor Carolyn Sue, MBBS, PhD, FRACP, is an internationally recognised clinician-scientist, a leader in Parkinson's disease and a medicine alum of UNSW who trained at Westmead Hospital and at Columbia University in the United States. Carolyn's experience, expertise and contributions to Parkinson's disease research have been widely recognised. She holds leadership roles in the Movement Disorder Society of Australia and New Zealand, and International Parkinson's disease and Movement Disorder Society, and is a Fellow of the Australian Academy of Medical Sciences. In 2019, Carolyn was awarded a member of the Order of Australia (AM) in recognition of her significant services to medicine. Professor Sue is leading a scientific review of the NTCELL clinical trial protocol and development plan in conjunction with a multi-disciplinary panel of scientific experts advising on various aspects of the NTCELL project. Professor Sue has resigned from her non-executive director position to focus all necessary attention on the role of CMO of NTCELL.
お知らせ • Jun 09Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific OfficerLiving Cell Technologies Limited announced the appointment of Dr. James A Mckenna as Chief Scientific Officer (`CSO') of the Company. Dr. Mckenna is an experienced research scientist who holds a PhD in biochemistry and molecular biology from the University of Melbourne. Dr. Mckenna has been a full-time research scientist for 23 years, with experience in academic science, commercial drug development and intellectual property generation. Most recently, he held a leadership position at an ASX listed biotechnology company where he managed and was involved in teams to advance pre-clinical and clinical research and development (R&D) programs for the purpose of achieving US Food and Drug Administration (FDA) registration. Dr. Mckenna's appointment coincides with LCT's corporate strategy to expand and diversify the Company's development pipeline. The role of CSO will include: research pertaining to drug candidate development, arrangement of pre-clinical and clinical studies, and liaison with intellectual property attorneys and pharmaceutical regulators. Dr. Mckenna commences the role of CSO on 19 June 2023.